Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Abbott 4Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Abbott 4Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abbott
 
4Q Revenues: $8.0 billion (+10%)

4Q Earnings: $1.5 billion (+28%)

FY Revenues: $30.0 billion (+14%)

FY Earnings: $4.9 billion (+35%)

Comments: Worldwide pharmaceutical sales were up 10% to $4.6 billion in the quarter, and up 14% to $16.7 billion for the year, driven by Humira, Niaspan, and the TriCor/Trilipix franchise. Humira sales in the quarter were $1.4 billion (+41%) and $4.5 billion for the year (+48%). TriCor/Trilipix sales in the quarter were $455 million (+16%) and $1.3 billion for the year (+10%). Niaspan span sales in the quarter were $221 million (+24%) and $786 million for the year (+19%). Depakote sales in the quarter were down 42% to $268 million, due to generic competition. U.S. Pharmaceutical sales were $2.5 billion in the quarter (+10%) and $8.5 billion for the year (+9%). Worldwide medical products sales increased 16% in the quarter, with 59% growth in global vascular sales driven by Xience V.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters